|Clinical applications of textural analysis in non-small cell lung cancer|
I Phillips, M Ajaz, V Ezhil, V Prakash, S Alobaidli, SJ McQuaid, C South, ...
The British journal of radiology 91 (1081), 20170267, 2018
|Stereotactic ablative body radiotherapy versus radical radiotherapy: comparing real-world outcomes in stage I lung cancer|
I Phillips, S Sandhu, M Lüchtenborg, S Harden
Clinical Oncology 31 (10), 681-687, 2019
|Comprehensive geriatric assessment in 326 older women with early breast cancer|
DO Okonji, R Sinha, I Phillips, D Fatz, A Ring
British journal of cancer 117 (7), 925-931, 2017
|Normal tissue complication probability (NTCP) modelling of severe acute mucositis using a novel oral mucosal surface organ at risk|
JA Dean, LC Welsh, KH Wong, A Aleksic, E Dunne, MR Islam, A Patel, ...
Clinical oncology 29 (4), 263-273, 2017
|Aspirin as a treatment for cancer|
I Phillips, R Langley, D Gilbert, A Ring
Clinical Oncology 25 (6), 333-335, 2013
|Androgen deprivation therapy and the re-emergence of parenteral estrogen in prostate cancer|
I Phillips, SIA Shah, T Duong, P Abel, RE Langley
Oncology & hematology review 10 (1), 42, 2014
|Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer|
M Stares, TE Ding, C Stratton, F Thomson, M Baxter, H Cagney, ...
ESMO open 7 (2), 100445, 2022
|Assessment of fully-automated atlas-based segmentation of novel oral mucosal surface organ-at-risk|
JA Dean, LC Welsh, D McQuaid, KH Wong, A Aleksic, E Dunne, MR Islam, ...
Radiotherapy and Oncology 119 (1), 166-171, 2016
|Hypoalbuminaemia as a prognostic biomarker of first-line treatment resistance in metastatic non-small cell lung cancer|
M Stares, A Swan, K Cumming, TE Ding, J Leach, C Stratton, F Thomson, ...
Frontiers in Nutrition 8, 734735, 2021
|The stability of imaging biomarkers in radiomics: a framework for evaluation|
HYC Wang, EM Donovan, A Nisbet, CP South, S Alobaidli, V Ezhil, ...
Physics in Medicine & Biology 64 (16), 165012, 2019
|Nutritional status and symptom burden in advanced non-small cell lung cancer: results of the dietetic assessment and intervention in lung cancer (DAIL) trial|
I Phillips, L Allan, A Hug, N Westran, C Heinemann, M Hewish, A Mehta, ...
BMJ supportive & palliative care 13 (e1), e213-e219, 2023
|Prehabilitation services for people diagnosed with cancer in Scotland–Current practice, barriers and challenges to implementation|
D Provan, G McLean, SJ Moug, I Phillips, AS Anderson
The Surgeon 20 (5), 284-290, 2022
|Dietetic assessment and intervention in lung cancer|
I Phillips, A Hug, L Allan, V Ezhil
Current Opinion in Supportive and Palliative Care 13 (4), 311-315, 2019
|Optimising patient fitness: strategies to reduce the effects of cancer cachexia in patients with advanced lung cancer|
I Phillips, S Kestenbaum
Current Opinion in Supportive and Palliative Care 14 (4), 304-308, 2020
|Symptom burden strongly correlates with the need for a dietitian in advanced NSCLC|
I Philips, L Allan, A Hug, N Westram, C Heinemann, M Hewish, A Mehta, ...
Annual BTOG/Lung Cancer, 2020
|Rate of cachexia in lung cancer|
A Hug, I Phillips, L Allan, V Ezhil
European Journal of Surgical Oncology 42 (11), S227, 2016
|Early mortality following radiotherapy–meeting standards and improving patient selection.|
A Lerner, I Phillips, V Ezhil
Clinical Oncology 27, S5-S6, 2015
|Optimising outcomes in non small cell lung cancer: targeting cancer cachexia|
I Phillips, M Stares, L Allan, J Sayers, R Skipworth, B Laird
Frontiers in Bioscience-Landmark 27 (4), 129, 2022
|Early dietitian referral in lung cancer: use of machine learning|
M Chung, I Phillips, L Allan, N Westran, A Hug, PM Evans
BMJ Supportive & Palliative Care, 2022
|Scottish Immunotherapy Prognostic Score: biomarker of systemic inflammation predicts response to first-line pembrolizumab for metastatic non-small cell lung cancer|
TG Ding, F Thomson, C Stratton, K Cumming, C Barrie, K Maclennan, ...
Lung Cancer 156, S43, 2021